Dr. Jeffrey L. Cummings In The News
![K.T.N.V. T.V. ABC 13](/sites/default/files/styles/100_width_25_height/public/news_source/logo/KTNV-TV.png?itok=fuEYrB8V)
![Las Vegas Review Journal](/sites/default/files/styles/100_width_25_height/public/news_source/logo/las-vegas-review-journal.jpg?itok=IX9YBkgU)
Spiegel Gesundheit
For the first time, the US FDA has approved a drug that is supposed to counteract a cause of Alzheimer's disease. But it is highly controversial.
Practical Neurology
Aducanumab is the first disease-modifying treatment to be approved for Alzheimer's Disease (AD) and the first to target amyloid ß (Aß), which is one of the earliest causative steps in the pathophysiology of AD.
![Newswise](/sites/default/files/styles/100_width_25_height/public/news_source/logo/newswise.png?itok=_CT4oU3W)
![Reuters](/sites/default/files/styles/100_width_25_height/public/news_source/logo/reuters.png?itok=h5i5oG90)
![Yahoo!](/sites/default/files/styles/100_width_25_height/public/news_source/logo/yahoo-logo.png?itok=_QObPPuO)
MarketScreener
The U.S. FDA on Monday is expected to give its thumbs up or down on Biogen Inc's aducanumab, a decision that will affect the future of Alzheimer's disease research and treatment and show the agency's willingness to approve badly needed medicines based on less than definitive data.